# Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

> **NCT01721525** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Cancer

## Interventions

- **DRUG:** Afatinib, Ribavirin, and weekly carboplatin/paclitaxel

## Key facts

- **NCT ID:** NCT01721525
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2017-10-16
- **Final completion:** 2017-10-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-10-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721525, "Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT01721525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*